Doctors Note Logo

Published on: 5/21/2026

Why Breo Ellipta Is Prescribed for Persistent Asthma: The Lung Science

Persistent asthma often remains uncontrolled with inhaled corticosteroids alone. Breo Ellipta combines fluticasone furoate and vilanterol in a single once-daily inhaler to both reduce airway inflammation and relax bronchial muscles, improving lung function and lowering the risk of exacerbations.

There are several important factors to consider, including clinical benefits, proper inhaler technique, potential side effects, and safety precautions. See below for the complete details to guide your next steps in asthma management.

answer background

Explanation

Why Breo Ellipta Is Prescribed for Persistent Asthma: The Lung Science

Persistent asthma is a chronic lung condition where inflammation and narrowing of the airways cause recurring symptoms like wheezing, coughing, chest tightness, and shortness of breath. For many people, inhaled corticosteroids (ICS) alone may not fully control these symptoms. That's where Breo Ellipta steps in. This once-daily inhaler combines two powerful medicines to help maintain lasting relief and improve lung function.

In this article, we'll explore:

  • What Breo Ellipta is
  • How it works in the lungs
  • Clinical benefits for persistent asthma control
  • Who should consider it
  • Proper use and safety considerations
  • Additional steps to support your asthma management

As always, speak to a doctor about anything that could be life threatening or serious.


What Is Breo Ellipta?

Breo Ellipta is a prescription inhaler containing two active ingredients:

  • Fluticasone furoate (an inhaled corticosteroid)
  • Vilanterol (a long-acting beta₂-agonist)

Together, these medicines address two key aspects of persistent asthma:

  1. Inflammation (corticosteroid effect)
  2. Bronchoconstriction (long-acting bronchodilator effect)

By combining them in one device, Breo Ellipta offers convenience and a consistent dosing schedule.


How Breo Ellipta Works: The Lung Science

Asthma involves chronic inflammation of the airways plus periodic tightening of the surrounding smooth muscle. Breo Ellipta targets both:

  1. Reducing Inflammation

    • Fluticasone furoate settles into the airway lining.
    • It decreases swelling and red blood cell migration.
    • Over time, tissues become less reactive to triggers like allergens, cold air, or exercise.
  2. Relaxing Airway Muscles

    • Vilanterol binds to beta₂-receptors on smooth muscle cells.
    • This causes the muscle to relax, widening the bronchial tubes.
    • Improved airflow helps you breathe more easily throughout the day.

Because both actions happen simultaneously, Breo Ellipta supports ongoing control of asthma symptoms and helps prevent flare-ups.


Benefits of Breo Ellipta for Persistent Asthma Control

Clinical studies demonstrate multiple advantages for people whose asthma remains uncontrolled on low- or medium-dose ICS alone. Key benefits include:

  • Improved Lung Function
    • Higher FEV₁ (forced expiratory volume) scores over 24 hours
  • Fewer Exacerbations
    • Reduced risk of asthma attacks requiring oral steroids or hospitalization
  • Once-Daily Dosing
    • Simplifies treatment schedules, boosting adherence
  • Rapid Onset
    • Bronchodilation begins within minutes of inhalation
  • Quality of Life
    • Better symptom control leads to fewer activity limitations

These outcomes contribute to more reliable, long-term asthma management.


Clinical Evidence

Several randomized controlled trials provide the evidence base for Breo Ellipta:

  • Study A compared Breo Ellipta to fluticasone alone, showing a 20–30% reduction in exacerbations over 24 weeks.
  • Study B showed significant lung function improvement versus vilanterol alone, with FEV₁ gains maintained throughout the dosing interval.
  • Real-world data suggest higher patient satisfaction and treatment persistence compared to multiple-inhaler regimens.

These findings support its role in enhancing persistent asthma control for people inadequately managed on monotherapy.


Who Should Consider Breo Ellipta?

Breo Ellipta is generally prescribed for adults and adolescents (12 years and older) with:

  • Moderate to Severe Persistent Asthma
  • Symptoms uncontrolled on low- or medium-dose ICS
  • A history of frequent night awakenings or asthma attacks
  • A need for a maintenance inhaler that simplifies dosing

It is not a rescue inhaler. For sudden breathing problems, you still need a fast-acting reliever (e.g., albuterol).


How to Use Breo Ellipta

Proper technique and adherence are essential:

  1. Check the Dose Counter
    • Displays remaining inhalations.
  2. Open the Device
    • Slide the cover until you hear a click.
  3. Exhale Gently Away
    • Don't blow into the mouthpiece.
  4. Inhale Steadily and Deeply
    • Hold breath for 3–4 seconds to deposit medication in the lungs.
  5. Close the Inhaler
    • Rinse your mouth after each use to reduce the risk of thrush.

Take Breo Ellipta once every 24 hours, at the same time each day, to maintain steady medication levels.


Possible Side Effects and Precautions

While many people tolerate Breo Ellipta well, be aware of:

Common side effects

  • Headache
  • Nasopharyngitis (cold-like symptoms)
  • Throat irritation

Less common but serious

  • Pneumonia (especially in older adults)
  • Adrenal suppression (with high-dose ICS over time)
  • Paradoxical bronchospasm (rare)

Precautions

  • Not for acute asthma attacks
  • Monitor growth in children on long-term ICS therapy
  • Use caution if you have heart disease, diabetes, or osteoporosis

Always tell your doctor about all other medications and health conditions.


Supporting Your Asthma Management

Medication is only one part of the picture. To optimize persistent asthma control, consider:

  • Trigger Identification and Avoidance
    • Pollen, dust mites, smoke, pet dander, exercise, cold air
  • Asthma Action Plan
    • Written guidance on daily management and handling flare-ups
  • Regular Monitoring
    • Peak flow measurements at home
    • Periodic lung function tests with your provider
  • Lifestyle Measures
    • Maintain a healthy weight
    • Stay active, but use your reliever inhaler before exercise if needed
  • Stress Management
    • Practice relaxation, since stress can worsen symptoms

If you're unsure whether your symptoms are well-controlled, using a free AI-powered Bronchial Asthma symptom checker can help you gain insight into your condition and prepare meaningful questions for your next doctor's visit.


Speak to a Doctor

Breo Ellipta can be a cornerstone of effective, once-daily therapy for those with persistent asthma. However, every person's condition is unique. If you experience:

  • Frequent or severe asthma attacks
  • Sudden worsening of symptoms
  • Any breathing difficulty that feels life threatening

…seek medical attention immediately.

For ongoing care, speak to a doctor about whether Breo Ellipta fits your asthma management plan. They can tailor treatment, monitor for side effects, and adjust doses as needed.


Persistent asthma control is within reach with the right combination of medication, self-management, and professional support. Breo Ellipta's dual action on inflammation and bronchoconstriction offers reliable, once-daily relief—helping you breathe easier day after day.

(References)

  • * O'Byrne PM, Barnes PJ, Bleecker ER, et al. Fluticasone furoate/vilanterol and airway inflammation in asthma. Respir Res. 2016 Apr 4;17(1):37. doi: 10.1186/s12931-016-0352-0. PMID: 27040409; PMCID: PMC4820847.

  • * Samaan T, Taneja A, Sethi S, Salgado M. Fluticasone Furoate and Vilanterol Trifenatate as a Single Inhaler in Adolescent and Adult Patients With Asthma: A Review. J Pharm Pract. 2018 Jun;31(3):360-366. doi: 10.1177/0897190017726529. Epub 2017 Aug 25. PMID: 28848419.

  • * Dhillon S. Fluticasone Furoate/Vilanterol: A Review of Its Use in Asthma. Drugs. 2013 Oct;73(15):1713-25. doi: 10.1007/s40265-013-0133-7. PMID: 24057829.

  • * Lipworth B, Lipworth S. Once-daily fluticasone furoate/vilanterol in asthma: an update for clinicians. Expert Rev Respir Med. 2018 Mar;12(3):215-220. doi: 10.1080/17476348.2018.1428387. Epub 2017 Nov 26. PMID: 29339395.

  • * Khurana R, Vashisht P, Saini N, Kaur M. Fluticasone Furoate/Vilanterol for the Treatment of Asthma: An Evidence-Based Review. Clin Drug Investig. 2017 Apr;37(4):307-316. doi: 10.1007/s40261-017-0498-6. PMID: 28270764.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.